Interviews with Pharma and Biotech Global Leaders
Refine Search
Pharmaceutical
For several years, pharma analysts have predicted varying degrees of impact from nascent blockchain technologies. While some suggest wholesale revolution is in the offing, others anticipate more incremental evolution for a conservative industry that is traditionally resistant to change. 23 July 2018
Pharmaceutical
Janssen has been on a good run of form recently. 16 July 2018
Biotechnology
In March 2018, Celgene announced its intention to co-develop and co-market bb2121, a bluebird bio CAR-T cell therapy for relapsed multiple myeloma. In conversation with The Pharma Letter, Tuomo Pätsi, worldwide president for hematology and oncology markets, makes a strong case for the drug. 11 July 2018
Biotechnology
When Seattle Genetics announced it had bought exclusive global rights to an an exciting new antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), shares in the candidate’s developer shot up by a third. 9 July 2018
Biotechnology
Since it first received US approval for thyroid cancer in February 2015, excitement around Eisai’s Lenvima (lenvatinib mesylate) as one of the hottest properties in oncology has steadily been growing. 4 July 2018
Pharmaceutical
Pharma companies sometimes need to be aware of advances in wearable technology that threaten to take market share away from their medicines, but such devices can also work well when used in conjunction with drugs. 2 July 2018
Pharmaceutical
Jesus Gomez-Navarro, vice president, head of oncology clinical research and development at Takeda Oncology, talks of three elements to the unit’s R&D strategy and three highlights in its pipeline when talking to The Pharma Letter about the most exciting abstracts being presented on the company’s cancer candidates at two major conferences this month. 20 June 2018
Pharmaceutical
Ipsen has been in oncology for a long time — since the 1980s in fact. It's one of the field's top 20 companies. But in a market that’s turbulent, spilling over with established titans and up-and-comers alike, how does the French firm manage to maintain its edge? 15 June 2018
Pharmaceutical
In an oral presentation to be given at the annual meeting of the European League Against Rheumatism (EULAR), US-based Celgene will present a post hoc analysis of data from the PALACE trial program that suggest new, previously uncaptured benefits of Otezla (apremilast) against psoriatic arthritis. 14 June 2018
Biotechnology
Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle choices, markets for insulin are becoming ever more competitive. 30 May 2018
Biotechnology
Soaring obesity rates and the accompanying scourge of type 2 diabetes have done wonders for insulin kingpin Novo Nordisk’s bottom line over the last quarter-century. 23 May 2018
Pharmaceutical
Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck KGaA since 2015. Speaking to The Pharma Letter, she discusses her company’s quest to overcome the chronic disease ... 17 May 2018
Biotechnology
Big pharma has spent a lot of money founding or funding small firms recently. This is partly a strategic choice on the part of management - some have a surfeit of candidates, with limited resources and expertise in-house.
But for Dr Kemal Malik, innovation chief and Bayer board member, his firm’s investment in three cell and gene therapy companies looking at early stage science is about more than the economics of R&D. 11 May 2018
Biotechnology
A newcomer on the biologics scene expressing a vision to become a global player is nothing new, but it is a bold ambition when coming from CinnaGen, an Iranian biosimilars company that is only just starting its journey in the world’s major pharma markets. 30 April 2018
Biotechnology
Since the inception of the biopharmaceutical age in the 1980s, the share of the market held by large molecules has risen steadily to about a fifth, and growth in the sector continues inexorably at around 7.5%. 23 April 2018
Biosimilars
It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar monoclonal antibody (mAb) from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) with its copy of Remicade (infliximab). 13 April 2018
Pharmaceutical
If it were ever doubted that cannabis-based therapies would one day occupy space in certain specialists’ armamentaria, that time has now certainly passed. 11 April 2018
Pharmaceutical
For many patients, brands like Nurofen (ibuprofen) and Claritin (loratadine) are household names. They retain a prominent place on supermarket shelves and sell extremely well with an established consumer base despite having been off-patent for many years, with their cheaper generic counterparts invariably displayed alongside them. 5 April 2018
Pharmaceutical
Cardiovascular (CV) disease is the world’s biggest killer that will demand a specific and concerted effort if drugmakers are to tackle it, but one company is discovering that taking a unilateral approach is not the way to solving the challenges of this complex area. 19 March 2018
Pharmaceutical
The Pharma Letter discovers that Takeda’s vision in neuroscience is reminiscent of its approach in producing global vaccines, another massive healthcare challenge that the company has decided to confront head-on in recent years. 14 March 2018
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze